Literature DB >> 25721222

Comment on: "Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus".

Emanuel Raschi1, Elisabetta Poluzzi, Fabrizio De Ponti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25721222     DOI： 10.1007/s40262-015-0248-4

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  9 in total

1.  Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

Authors:  William B White; Christopher P Cannon; Simon R Heller; Steven E Nissen; Richard M Bergenstal; George L Bakris; Alfonso T Perez; Penny R Fleck; Cyrus R Mehta; Stuart Kupfer; Craig Wilson; William C Cushman; Faiez Zannad
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

2.  Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.

Authors:  Allen D Brinker; Jenna Lyndly; Joseph Tonning; David Moeny; Jonathan G Levine; Mark I Avigan
Journal:  Drug Saf       Date:  2013-12       Impact factor: 5.606

3.  Hepatotoxicity of alogliptin.

Authors:  Elizabeth Barbehenn; Sammy Almashat; Michael Carome; Sidney Wolfe
Journal:  Clin Pharmacokinet       Date:  2014-11       Impact factor: 6.447

4.  Alogliptin: concern about hepatotoxicity?

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2014-11       Impact factor: 6.447

5.  Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work.

Authors:  Ayako Suzuki; Raul J Andrade; Einar Bjornsson; M Isabel Lucena; William M Lee; Nancy A Yuen; Christine M Hunt; James W Freston
Journal:  Drug Saf       Date:  2010-06-01       Impact factor: 5.606

6.  Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database.

Authors:  Emanuel Raschi; Elisabetta Poluzzi; Ariola Koci; Paolo Caraceni; Fabrizio De Ponti
Journal:  World J Hepatol       Date:  2014-08-27

Review 7.  Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.

Authors:  Larry K Golightly; Caitlin C Drayna; Michael T McDermott
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

Review 8.  Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2014-09       Impact factor: 6.447

9.  Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting.

Authors:  Carlo Piccinni; Domenico Motola; Giulio Marchesini; Elisabetta Poluzzi
Journal:  Diabetes Care       Date:  2011-04-22       Impact factor: 19.112
  9 in total
  3 in total

1.  Author's reply to De Ponti et al.: "Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus".

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2015-04       Impact factor: 6.447

Review 2.  Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk.

Authors:  Emanuel Raschi; Fabrizio De Ponti
Journal:  World J Hepatol       Date:  2015-07-08

Review 3.  Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus.

Authors:  Kohei Kaku; Koichi Kisanuki; Mari Shibata; Takashi Oohira
Journal:  Drug Saf       Date:  2019-11       Impact factor: 5.606
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.